Strategies employing blockade of activating receptors expressed on MCs, including FcεRI, IL-4R, and thymic stromal lymphopoietin receptor (TSLPR) have shown promising clinical activity in many allergic diseases, in part by reducing MC activity48. This evidence concerns the gene FCER1A and allergic disease.